top of page

Free Biopharma Daily Stock Updates - 09/08/21

$XBI $132.31 -0.87%

 

Covid Updates

$NVAX -1.4% Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza. source



Pipeline Updates

$TPTX -1.5% Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference. source


$RYTM -2.3% Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome. source


$CRDF -4.6% Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival. source


$ALBO +2.6% Albireo Receives UK MHRA Approval of Bylvay® (odevixibat). source


$SELB -2.2% Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins. source


$CRTX -1.5% Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588. source


$CNTB -1.2% Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps. source


$PHAT-1.9% Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection. source


$SLNO -3.9% Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR. source


$IFRX +2.4% InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint. source


$BOLT-6.4% Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors. source


$TERN -4.6% Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201. source


$CALA +2.2% Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer. source


$ADMA -7.1% ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations. source


$LBPH +1.0% Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial. source


$IMCR +0.6% Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma. source


$GRTX -2.8% Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters. source


$HCM -1.0% HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China. source


$DSGN +4.1% Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1. source


$INMB -22.6%



Finance & Business Updates

$ALEC -19.0% Alector Provides Executive Leadership Update. source


$KDMN +71.1% Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business. source


 

Posted by FS

0 comments
bottom of page